How has Achieve Life Sciences's change in accrued liabilities changed year-over-year?

Achieve Life Sciences's change in accrued liabilities increased by 112.6% year-over-year, from -$2.06M to $261K.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Sionna Therapeutics, Inc. Common StockSION

-$3.46M+19.8%

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Achieve Life Sciences's change in accrued liabilities?: Achieve Life Sciences (ACHV) reported change in accrued liabilities of $261K in Q1 2026.
How has Achieve Life Sciences's change in accrued liabilities changed year-over-year?: Achieve Life Sciences's change in accrued liabilities increased by 112.6% year-over-year, from -$2.06M to $261K.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.